PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1424422
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1424422
The global consumer genomics market size is valued at US$ 1.23 Bn in 2023 and is expected to reach US$ 4.38 Bn by 2030, grow at a compound annual growth rate (CAGR) of 19.9% from 2023 to 2030.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023/2024: | US$ 1.23 Bn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023/2024 to 2030/2031 CAGR: | 19.90% | 2030/2031 Value Projection: | US$ 4.38 Bn |
Direct-to-consumer genetic tests (DTC-GT) are genetic tests sold directly to consumers to provide information about their genetic information (generally ancestry, some health traits, and health risks) from a saliva sample. Three main categories of genetic testing are currently available: clinic-based, direct-to-consumer, and provider-mediated genetic testing. Clinic-based genetic testing is ordered, interpreted, and disclosed by a physician or other healthcare professional through a traditional healthcare professional-patient relationship. Standard-of-care approaches to clinic-based genetic testing involve a pre-test consultation to identify and document potential genetic risk factors, select the most appropriate test, and discuss the benefits and limitations of testing to facilitate informed consent from the patient. By analyzing an individual's DNA, companies can provide insights into genetic heritage and lineage, often with geographic detailing. Some services interpret genetic variations to provide information on predispositions to certain health conditions, potential reactions to certain drugs (pharmacogenomics), and suggestions for lifestyle or nutrition. Rapid advancements in genomics technologies have made genetic testing more affordable and accessible, encouraging consumer adoption. There has been a surge in the popularity of direct-to-consumer (DTC) genetic testing kits as consumers seek convenient health insights without visiting healthcare facilities. People are increasingly interested in identifying potential health risks and taking preventive measures, which often involves genetic testing.
The increasing adoption of inorganic growth strategies such as partnerships by the key players in the market is expected to drive the growth of the market over the forecast period. For instance, in January 2022, the American Society of Human Genetics (ASHG) announced the launch of the ASHG Genetics and Genomics Impact Partnerships program. Illumina, a leader in next-generation genomic sequencing technologies, and Invitae, a leading medical genetics company, have joined as founding partners of ASHG Genetics and Genomics Impact Partnerships program.